Landscape Capital Management L.L.C. Purchases 23,086 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Landscape Capital Management L.L.C. grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 85.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 49,986 shares of the company's stock after purchasing an additional 23,086 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Apellis Pharmaceuticals were worth $1,595,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Cinctive Capital Management LP bought a new position in Apellis Pharmaceuticals during the 4th quarter worth about $2,776,000. Trexquant Investment LP bought a new stake in Apellis Pharmaceuticals in the 4th quarter valued at approximately $6,478,000. Geode Capital Management LLC grew its stake in shares of Apellis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company's stock worth $58,699,000 after acquiring an additional 28,426 shares in the last quarter. National Bank of Canada FI raised its holdings in shares of Apellis Pharmaceuticals by 266,361.5% in the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock valued at $44,214,000 after purchasing an additional 1,385,080 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in shares of Apellis Pharmaceuticals by 16.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 347,854 shares of the company's stock worth $11,100,000 after purchasing an additional 49,901 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CAO James George Chopas sold 1,096 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $33,351.28. Following the transaction, the chief accounting officer now directly owns 48,138 shares in the company, valued at approximately $1,464,839.34. This represents a 2.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Cedric Francois sold 13,551 shares of the company's stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $412,356.93. Following the transaction, the chief executive officer now owns 418,519 shares in the company, valued at $12,735,533.17. This represents a 3.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,238 shares of company stock valued at $1,857,510 over the last ninety days. 6.80% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS traded down $1.63 during mid-day trading on Thursday, reaching $17.98. 748,916 shares of the company's stock were exchanged, compared to its average volume of 2,117,432. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm has a market capitalization of $2.26 billion, a PE ratio of -8.86 and a beta of 0.85. Apellis Pharmaceuticals, Inc. has a one year low of $17.48 and a one year high of $57.85. The business's fifty day simple moving average is $25.19 and its two-hundred day simple moving average is $28.52.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.08. The company had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.73) earnings per share. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on APLS shares. Royal Bank of Canada cut their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research report on Monday, March 3rd. The Goldman Sachs Group decreased their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Scotiabank upped their price objective on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a research note on Wednesday, April 2nd. HC Wainwright reissued a "buy" rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Finally, Wedbush cut their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.59.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).